FourThought Financial Partners’s Corcept Therapeutics CORT Stock Holding History

FourThought Financial Partners’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.02M	Hold	11,720	–	–	0.08%	145
2026 Q1	$472K	Sell	11,720 -74	-0.6%	-$2.77K	0.04%	192
2025 Q4	$410K	Sell	11,794 -886	-7%	-$69.6K	0.03%	241
2025 Q3	$1.05M	Buy	12,680 +918	+8%	+$66.4K	0.09%	134
2025 Q2	$863K	Sell	11,762 -644	-5%	-$46.7K	0.09%	146
2025 Q1	$1.42M	Hold	12,406	–	–	0.15%	114
2024 Q4	$625K	Buy	+12,406	New	+$650K	0.06%	167
2024 Q2	–	Sell	-12,406	Closed	-$313K	–	215
2024 Q1	$313K	Hold	12,406	–	–	0.04%	248
2023 Q4	$403K	Hold	12,406	–	–	0.05%	213
2023 Q3	$338K	Hold	12,406	–	–	0.05%	221
2023 Q2	$276K	Hold	12,406	–	–	0.04%	264
2023 Q1	$269K	Hold	12,406	–	–	0.04%	265
2022 Q4	$252K	Buy	+12,406	New	+$311K	0.04%	276

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FourThought Financial Partners's CORT Position: Q2 2026 in Review

FourThought Financial Partners held its Corcept Therapeutics (CORT) position steady in Q2 2026 at 11,720 shares worth $1.02M. The position accounts for 0.08% of the portfolio, ranked #145.

FourThought Financial Partners first reported a position in CORT in Q4 2022 and has held it in 13 quarters since. The position peaked at $1.42M in Q1 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

FourThought Financial Partners held 11,720 shares of Corcept Therapeutics worth $1.02M as of Q2 2026.
FourThought Financial Partners left its Corcept Therapeutics share count unchanged in Q2 2026.
Corcept Therapeutics made up 0.08% of FourThought Financial Partners's portfolio in Q2 2026, its #145 holding.
FourThought Financial Partners first reported a position in Corcept Therapeutics in Q4 2022 and has held it in 13 quarters since.
FourThought Financial Partners's Corcept Therapeutics position peaked at $1.42M in Q1 2025.
423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on FourThought Financial Partners's 13F filing for Q2 2026, filed 12 Aug 2026.